Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

Inclusion Criteria:

All participants (with mild, moderate or severe renal impairment, end stage renal disease,
or healthy):

- a female must be non-pregnant, non-breast feeding and if she is of reproductive
potential: must agree to use (and/or have their partner use) two acceptable methods of
birth control beginning at screening, throughout the study and until 2 weeks after the
last dosing of study drug

- a female of non-childbearing potential: must have undergone a sterilization procedure
at least 6 months prior to the first dose or be postmenopausal with amenorrhea for at
least 1 year prior to the first dose

- a non-vasectomized male participant must agree to use a condom with spermicide or
abstain from sexual intercourse from the first dose until 90 days after the last dose
of study drug

- a male participant must agree not to donate sperm from dosing until 90 days after the
last dose of study drug

- has a body mass index (BMI) ≤ 40.0 kg/m^2

- is a non-smoker or moderate smoker (≤ 20 cigarettes/day or the equivalent)

Participants with mild, moderate or severe renal impairment or end stage renal disease:

- has a clinical diagnosis of renal impairment and meets the protocol-specified renal
impairment function qualifications at the prestudy visit (screening)

Healthy participants:

- has baseline creatinine clearance (CLcr) ≥ 90 mL/min based on Cockcroft-Gault equation

- is judged to be in good health based on medical history, physical examination, vital
signs, pulse oximetry, and laboratory safety tests

Exclusion Criteria:

All participants (with mild, moderate or severe renal impairment, end stage renal disease,
or healthy):

- is mentally or legally incapacitated or has significant emotional problems at the time
of the screening visit or expected during the conduct of the study.

- history or presence of clinically significant medical or psychiatric condition or
disease

- history of stroke, chronic seizures, or major neurological disorders

- history of malignant neoplastic disease

- history or presence of alcoholism or drug abuse within the past 6 months

- female participant who is pregnant or lactating

Participants with mild, moderate or severe renal impairment:

- has had a renal transplant or has had nephrectomy

- has uncontrolled type 2 diabetes mellitus (T2DM), a history of Type 1 diabetes, or
ketoacidosis

- history of significant endocrine, gastrointestinal, cardiovascular, hematological,
immunological, respiratory, or genitourinary diseases

Participants with end stage renal disease (ESRD):

- had a failed renal allograft within the last 2 years prior to the first dose, or a
successful renal allograft

- has uncontrolled T2DM, a history of Type 1 diabetes, or ketoacidosis

- history of significant endocrine, gastrointestinal, cardiovascular, hematological,
immunological, respiratory, or genitourinary diseases

Healthy participants:

- history of hypoglycemia, glucose intolerance, T2DM, or ketoacidosis

- history of clinically significant endocrine, gastrointestinal, cardiovascular,
hematological, hepatic, immunological, renal, respiratory, or genitourinary
abnormalities or diseases.